Navigation Links
Regeneron Reports Second Quarter 2011 Financial and Operating Results
Date:7/28/2011

TARRYTOWN, N.Y., July 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2011 and provided an update on development programs and upcoming milestones.  

Clinical Programs UpdateEYLEA™ (aflibercept injection)– Ophthalmologic DiseasesEYLEA™, also known as VEGF Trap-Eye, is a fusion protein locally administered in the eye that is designed to bind Vascular Endothelial Growth Factor-A (VEGF-A) and Placental Growth Factor (PlGF), proteins that are involved in the abnormal growth of new blood vessels.  Regeneron maintains exclusive rights to EYLEA™ in the United States.  Bayer HealthCare LLC has rights to market EYLEA™ outside the U.S., where the companies will share equally in profits from any future sales of the product candidate.

In April 2011, the U.S. Food and Drug Administration (FDA) granted the Company's request for Priority Review of its Biologics License Application (BLA) for EYLEA™ for the treatment of the neovascular form of age-related macular degeneration (wet AMD) and set August 20, 2011 as the target date for an FDA decision. In June 2011, the Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA unanimously recommended that the FDA approve EYLEA™.  

Also in June 2011, Bayer Healthcare submitted regulatory applications for marketing approval for EYLEA™ for the treatment of wet AMD in the European Union and in Japan.  As previously disclosed, Regeneron intends to submit an additional regulatory application for marketing approval for EYLEA™ in a second indication, central retinal vein occlusion (CRVO), in the U.S. in the second half of 2011, and Bayer HealthCare plans to submit a similar regulatory application in Europe in 2012.

During the second quarter of 2011, Regeneron and Bayer Healthcare each initiated a Phase 3 study of EYLEA™ in
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Cardiac Dimensions ® , Inc. ... the TITAN II clinical trial of its enhanced ... improvements in mitral regurgitation, functional improvement, quality of ... and efficacy data, which was consistent with previous ... at the 26 th annual Transcatheter Cardiovascular ...
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. ... Phase 2 clinical program of NP001 for the treatment ... disease) are being highlighted today in an oral ... Research Group , being held in Bloomington, ... post hoc  analysis, administration of a high dose of ...
(Date:9/17/2014)... MILL VALLEY, Calif. , Sept. 17, 2014 ... a partnership in the fight against sarcoma. Under ... Alliance Suzanne Renee Leider Memorial Assistance Fund. ... to reimburse sarcoma patients for expenses directly related ... specialist. Scientific literature reinforces the importance of this ...
Breaking Medicine Technology:Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 2Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 3
(Date:9/17/2014)... Historically, spaceflight has been reserved for the very ... meet the highest physical and psychological standards to ... the advent of commercial spaceflight, average people can ... has had very little information about what medical ... in the spaceflight environment, as most medical conditions ...
(Date:9/17/2014)... People who struggle to distinguish between a business strategy and ... get the answer by reading Per Wickstrom’s latest blog post. ... business plan and a business strategy are both strategic – ... way I view it is that a business plan is ... two.” , According to the blog post, a business ...
(Date:9/17/2014)... manipulation these sound like the ideas of ... are components of an exciting new approach to ... models of metastatic prostate cancer, scientists at Virginia ... Molecular Medicine and Johns Hopkins Medical Institutions have ... that could revolutionize doctors, ability to see tumors ...
(Date:9/17/2014)... N.J. (PRWEB) September 17, 2014 ... advanced delivery technologies and development solutions for drugs, ... launch of OptiPact™, an integrated service and technology ... compaction, and provided from the company’s 450,000 sq. ... describes Catalent’s ability to integrate optimal formulation, development, ...
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Positive messages ... some people kick the habit, a new study suggests. ... responded better to "loss-framed" messages about the harmful effects ... quit whenever they want benefit more from "gain-framed," or ... The researchers concluded that using a mix of ...
Breaking Medicine News(10 mins):Health News:Space: The final frontier… open to the public 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2
... University,s Physical Activity and Public Health Laboratory, active commuting ... can be an easy, effective and efficient way to ... Wittman, a K-State senior in kinesiology, Olathe, worked with ... of kinesiology, on the active commuting research. The project ...
... April 13 Mylan Inc. (Nasdaq: MYL ... banker,Andrew G. Cuneo as vice president of Global Business ... and strategic,efforts in close alignment with the company,s executive ... Chairman and CEO Robert J. Coury said: "Drew brings ...
... 13 Lionbridge,Technologies, Inc. (Nasdaq: ... testing,and development services today announced an alliance ... Enterprise Content Management (ECM) software,designed to ensure ... management solutions for pharmaceutical companies and other,organizations. ...
... could one day quickly detect if treatment is working, study ... technique that can detect subtle changes in cancer cells contained ... tissue may one day be used by doctors to better ... , "Currently, we don,t know what,s going on in a ...
... Though a high-fiber diet has long been considered good ... Medical College of Georgia researchers have discovered a reason ... Researchers report in the April issue of Cancer ... butyrate, a metabolite produced by fiber-eating bacteria in the ...
... 15th, there will be a,Capitol Hill briefing called ... and Mental Illness." Author and award winning ... HELP USA,Lamp Community, the National Alliance on Mental ... H.O.M.E. have join forces to host this,important briefing. ...
Cached Medicine News:Health News:Survey research looks at attitudes, obstacles to walking and biking to work 2Health News:Survey research looks at attitudes, obstacles to walking and biking to work 3Health News:Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development 2Health News:Lionbridge Announces Partnership with Open Text to Streamline Regulatory Compliance Solutions for Pharmaceutical Companies 2Health News:A Drop of Blood May Help Assess Cancer Therapy 2Health News:Colon cancer shuts down receptor that could shut it down 2Health News:Colon cancer shuts down receptor that could shut it down 3Health News:Capitol Hill Briefing Scheduled for April 15th About Homelessness and Mental Illness 2Health News:Capitol Hill Briefing Scheduled for April 15th About Homelessness and Mental Illness 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: